Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases.
Market
Renal, cardiovascular, and metabolic diseases
Location
South San Francisco,
California,
USA
Coinvestors
Frazier Life Sciences, Deep Track Capital, Janus Henderson Investors, Logos Capital, Third Rock Ventures, ARCH Venture Partners, Matrix Capital Management, GV, General Catalyst, Andreessen Horowitz (a16z), Foresite Capital, Woodline Partners LP, Casdin Capital, Piper Heartland Healthcare Capital, Moore Strategic Ventures